苦参素联合肝动脉插管治疗肝癌75例疗效观察(英文)  

Effect of Marin solution combined with transcatheter arterial embolization on 75 cases of primary hepatocelluar carcinoma

作　　者：刘启荣[1] 李裕华[1] 

机构地区：[1]重庆市急救医疗中心,四川重庆400014

出　　处：《中国现代医学杂志》2004年第9期33-35,共3页China Journal of Modern Medicine

摘　　要：目的　观察苦参素与肝动脉插管化疗 (TAE)术治疗中晚期肝癌疗效。方法　 75例确诊为中、晚期肝癌患者随机分为治疗组 4 0例和对照组 35例 ,治疗组用苦参素注射液联合肝动脉插管化疗 (TAE)术和对照组用TAE术治疗 ,两组同时加用云芝胞内糖肽胶囊 (云星胶囊 )免疫增强剂口服。结果　治疗 8个月后 ,治疗组改善临床症状 ,提高疗效均明显优于对照组 (P <0 .0 5 ) ,同时副作用明显低于对照组 (P <0 .0 5 ) ,肿瘤退缩率与生存率两组无显著性差异 (P >0 .0 5 )。结论　苦参素能提高介入化疗治疗原发性肝癌中晚期患者的疗效 。Objective: To investigate the effect of Marin solution combined with transcatheter arterial embolization(TAE) on liver cancer . Methods: 75 cases of moderate and advanced primary hepatocelluar carcinoma were randomly divided into two groups:test group( n =40 cases) and control group ( n =35 cases). Patients in test group were treated by Marin solution combined with TAE, and patients in control group were treated by TAE, both groups were treated by Knestin .Results: After therapy for 8 months, symptoms in control group were improved , the effect was better than that of control group( P <0.05),and the side effect was significantly less than that of control group ( P <0.05). There was no significant difference in the rate of tumor survivaL and tumor regression between two groups ( P <0.05).Conclusions: Marin solution can improve the effect of TAE on liver cancer and prevent side effects.

关 键 词：苦参素注射液 TAE术 原发性肝癌(中晚期) 

分 类 号：R735.7[医药卫生—肿瘤]